Pharvaris (PHVS) Net Cash Flow (2020 - 2026)
Pharvaris' (PHVS) quarterly Net Cash Flow came in at -$57.2 million in Q1 2026, down 40.55% YoY from -$96.3 million in Q1 2025, and down 30.46% on a QoQ basis from -$43.9 million in Q4 2025.
Pharvaris (PHVS) Net Cash Flow (2020 - 2026) Analysis & Trends
Pharvaris (PHVS) has 7 years of Net Cash Flow data on file, last reported at -$57.2 million in Q1 2026.
- Quarterly Net Cash Flow fell 40.55% year-over-year to -$57.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $16.6 million (up 111.65% YoY) and the FY2025 annual result came in at $26.4 million, up 120.67% from the prior year.
- Net Cash Flow retreated to -$57.2 million in Q1 2026, from -$43.9 million in the prior quarter.
- In the past five years, Net Cash Flow ranged from a high of $19647.1 billion in Q2 2023 to a low of -$19641.1 billion in Q3 2023.
- A 5-year average of $356.6 million and a median of -$27.1 million in 2023 frame the typical range for Net Cash Flow.
- The widest YoY moves for Net Cash Flow: up 385414451.59% in 2023, down 127777546.09% in 2023.
- Tracing PHVS's Net Cash Flow over 5 years: stood at -$21.0 million in 2022, then surged by 1318.07% to $256.0 million in 2023, then tumbled by 114.42% to -$36.9 million in 2024, then dropped by 18.81% to -$43.9 million in 2025, then tumbled by 30.46% to -$57.2 million in 2026.
- The last three Net Cash Flow figures came in at -$57.2 million (Q1 2026), -$43.9 million (Q4 2025), and $151.7 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 374.50 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 407.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 17.81 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 225.59 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -496,000.00 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -37.14 Mn |
| 10 | Pharvaris | 2.29 Bn | 1.92 Bn | - | 79.09 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 79.09 Mn |
| Jun 30, 2026 | 79.09 Mn |
| Mar 31, 2026 | -57.23 Mn |
| Mar 31, 2026 | -57.23 Mn |
| Dec 31, 2025 | -43.86 Mn |
| Dec 31, 2025 | -43.86 Mn |
| Sep 30, 2025 | 151.68 Mn |
| Sep 30, 2025 | 151.68 Mn |
| Jun 30, 2025 | -33.94 Mn |
| Jun 30, 2025 | -33.94 Mn |
| Mar 31, 2025 | -40.72 Mn |
| Mar 31, 2025 | -40.72 Mn |
| Dec 31, 2024 | -36.92 Mn |
| Dec 31, 2024 | -36.92 Mn |
| Sep 30, 2024 | -35.78 Mn |
| Sep 30, 2024 | -35.78 Mn |
| Jun 30, 2024 | -29.51 Mn |
| Jun 30, 2024 | -29.51 Mn |
| Mar 31, 2024 | -25.49 Mn |
| Mar 31, 2024 | -25.49 Mn |